PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · May 2021 · 1 min read
In brief
In brief
This study identifies a pathogenic subset of hepatic Th17 cells (ihTh17) that drive NAFLD progression through PKM2-dependent glycolytic metabolism. Targeting this metabolic pathway with glycolysis inhibitors or PKM2 deletion reduces liver inflammation and disease severity, offering potential therapeutic strategies for NAFLD treatment.
Written by the GCMD Library team from the article.
Statements in this article
A distinct population of inflammatory hepatic CXCR3+Th17 (ihTh17) cells is sufficient to exacerbate NAFLD pathogenesis.
Hepatic ihTh17 cell accumulation is dependent on the liver microenvironment and CXCR3 axis activation.
The pathogenic potential of ihTh17 cells correlates with increased chromatin accessibility, glycolytic output, and concomitant production of IL-17A, IFNγ, and TNFα.
Modulation of glycolysis using 2-DG is sufficient to reverse ihTh17-centric inflammatory vigor and NAFLD severity.
Cell-specific PKM2 deletion is sufficient to reverse ihTh17-centric inflammatory vigor and NAFLD severity.
ihTh17 cell characteristics, CXCR3 axis activation, and hepatic expression of glycolytic genes are conserved in human NAFLD.
The steatotic liver microenvironment regulates Th17 cell accumulation, metabolism, and competence toward an ihTh17 fate.
